Camber1jpj (Camber1jpg)
Tadalafil Tablet, Film Coated
Product Images NDC 31722-643
14 FDA label images from Camber Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 31722-643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Tadalafil.jpg (Tadalafil)
Tadalafil Tablets USP 2.5 mg film-coated tablets in a 30-count package by Camber Pharmaceuticals, Inc. The label specifies once-daily use without splitting tablets, includes storage instructions, and lists a U.S. contact number. It features a barcode and manufacturing details from Hetero Labs Limited, India.*
Tadalafil10mg.jpg (Tadalafil10mg)
Label for Tadalafil Tablets USP 10 mg by Camber Pharmaceuticals, Inc. The label includes dosage form as film-coated tablets, prescription only indication, and a 30-tablet count. It shows storage instructions, warnings, and manufacturer details. The NDC number 31722-645-30 is displayed along with a barcode.*
Tadalafil20mg.jpg (Tadalafil20mg)
Label for Tadalafil 20 mg film-coated tablets by Camber Pharmaceuticals, Inc. It includes the proprietary name, strength, dosage form, NDC 31722-646-30, package count of 30 tablets, and storage instructions. The label features warnings about tablet splitting and dosage and provides contact information and barcode.*
Tadalafil5mg.jpg (Tadalafil5mg)
Tadalafil 5 mg film-coated tablets label from Camber Pharmaceuticals, Inc. The label states the active ingredient is tadalafil USP, with a 5 mg strength per tablet. The package contains 30 tablets and is for prescription use only. It includes storage instructions, a warning to keep out of reach of children, and manufacturing information for Hetero Labs Limited in India.*
Tadalafilfigure1.jpg (Tadalafilfigure1)
Four line graphs depicting the difference in blood pressure measurements (systolic and diastolic) over time (in hours) comparing Tadalafil versus placebo. The graphs show data for Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP with timepoints from 0 to 96 hours on the x-axes and blood pressure differences in mmHg on the y-axes.*
Tadalafilfigure2.jpg (Tadalafilfigure2)
This image contains two line graphs showing blood pressure (mmHg) over 24 hours post-dose. The top graph displays standing systolic blood pressure changes, and the bottom graph shows supine systolic blood pressure changes. Both compare tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg over time.*
Tadalafilfigure4.jpg (Tadalafilfigure4)
Line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin at different dosages and times. The x-axis represents time after administration, and the y-axis shows systolic blood pressure changes. The graph compares four groups based on tadalafil dose (10 mg or 20 mg) and timing (08:00 and 20:00) versus placebo with doxazosin.*
Tadalafilfigure5.jpg (Tadalafilfigure5)
A line graph depicting plasma tadalafil concentration (µg/L) over time (hours). The graph compares three dosage scenarios: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and a once-daily 5-mg tadalafil dose following 5 consecutive days of administration. Error bars indicating variability are shown for each data point.*
Tadalfilfigure6.jpg (Tadalafilfigure6)
A line graph comparing the change from baseline in IPSS total score over a 12-week treatment period for Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, with Tadalafil demonstrating a greater reduction compared to placebo. Statistical significance is indicated with p<0.01.*
Tadalafilfigure7.jpg (Tadalafilfigure7)
A line graph showing change from baseline in IPSS Total Score over 12 weeks for Tadalafil 5 mg versus placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the score change. The graph indicates greater score reduction with Tadalafil 5 mg compared to placebo.*
Tadalafilfigure8 (Tadalafilfigure8)
A line graph depicting the least squares mean change from baseline over 26 weeks of therapy. It compares Tadalafil/Finasteride versus Placebo/Finasteride treatment groups, showing data points with statistical significance indicated at various weeks during the study period.*
Tadalfilfigure9.jpg (Tadalafilfigure9)
Line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil and placebo. The x-axis represents treatment duration in weeks (0, 2, 4, 8, 12), and the y-axis represents change from baseline in IPSS score. Tadalafil group shows a greater decrease in score over time compared to placebo. Statistical significance (p<0.01) is indicated.*
Tadalafilstructure.jpg (Tadalafilstructure)
Chemical structure diagram of tadalafil, illustrating its molecular framework with labeled atoms and bonds.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
